Semaglutide 2.4mg (brand name Wegovy) is the most studied GLP-1 receptor agonist for weight management in history. The STEP (Semaglutide Treatment Effect in People with obesity) trial program enrolled over 10,000 participants across multiple studies, generating the dataset that led to FDA approval and fundamentally changed how medicine approaches obesity. Here's what the data actually says.

STEP 1: The Landmark Trial

Published: February 2021, New England Journal of Medicine
Participants: 1,961 adults with BMI ≥30 (or ≥27 with at least one weight-related comorbidity), without diabetes
Design: Randomized, double-blind, placebo-controlled. 2:1 ratio (semaglutide to placebo). 68-week duration.
Lifestyle intervention: Both groups received counseling on a 500-calorie deficit diet and 150 minutes of physical activity per week.

Results:

  • Semaglutide group: -14.9% body weight from baseline (mean)
  • Placebo group: -2.4% body weight from baseline
  • Placebo-adjusted difference: -12.4 percentage points
  • 86.4% of semaglutide participants lost ≥5% of body weight (vs 31.5% placebo)
  • 69.1% lost ≥10% (vs 12.0% placebo)
  • 50.5% lost ≥15% (vs 4.9% placebo)
  • 32.0% lost ≥20% (vs 1.7% placebo)

These numbers were unprecedented for a pharmaceutical weight loss intervention. The mean starting weight was about 232 lbs (105 kg), so a 14.9% loss translates to roughly 34.5 lbs over 68 weeks. But the distribution matters — about a third of participants lost 20% or more, while some lost less than 5%. Individual response varies significantly.

STEP 2: Semaglutide in Type 2 Diabetes

Published: March 2021, The Lancet
Participants: 1,210 adults with BMI ≥27 AND type 2 diabetes
Duration: 68 weeks

This trial was critical because people with type 2 diabetes are notoriously harder to treat for weight loss — diabetes medications often cause weight gain, and insulin resistance makes fat mobilization less efficient.

Results:

  • Semaglutide 2.4mg group: -9.6% body weight
  • Semaglutide 1.0mg group: -7.0% body weight
  • Placebo group: -3.4% body weight

Lower weight loss than STEP 1, as expected. But a nearly 10% reduction in patients with diabetes is still clinically significant — enough to improve glycemic control, reduce medication burden, and lower cardiovascular risk. Importantly, STEP 2 also showed meaningful HbA1c improvements, with many participants able to reduce or eliminate diabetes medications.

STEP 3: Intensive Behavioral Therapy

Published: February 2021, JAMA
Participants: 611 adults, no diabetes
Duration: 68 weeks
Unique feature: Participants received intensive behavioral therapy (IBT) — 30 individual counseling sessions over 68 weeks plus a low-calorie diet (1,000-1,200 kcal/day) for the first 8 weeks.

Results:

  • Semaglutide + IBT group: -16.0% body weight
  • Placebo + IBT group: -5.7% body weight

This is the "kitchen sink" trial — what happens when you combine the drug with the most aggressive behavioral intervention? An additional ~1 percentage point over STEP 1, suggesting that semaglutide does most of the heavy lifting, but intensive lifestyle support provides a modest additive benefit. For more on how exercise interacts with GLP-1 outcomes, see our dedicated breakdown.

STEP 4: What Happens When You Stop?

Published: March 2022, JAMA
Participants: 803 adults, no diabetes
Design: All participants received semaglutide 2.4mg for 20 weeks. Then randomized: half continued semaglutide, half switched to placebo for 48 more weeks.

This is arguably the most important STEP trial because it answers the question everyone asks: what happens when I stop taking it?

Results:

  • At 20 weeks (run-in period): both groups had lost ~10.6% of body weight
  • Continued semaglutide group at 68 weeks: -17.4% total (continued losing)
  • Switched to placebo at 68 weeks: -5.0% total (regained about two-thirds of their loss)

The withdrawal group regained an average of 11.6 percentage points of the weight they had lost during the run-in period. This is the result that led to the widespread understanding that GLP-1 medications are, for most people, a long-term treatment rather than a short-term fix.

This doesn't mean the weight regain is inevitable or complete. Some participants maintained a portion of their loss. But on average, stopping semaglutide results in significant regain — similar to what happens when you stop blood pressure medication and your blood pressure rises.

STEP 5: Two-Year Data

Published: October 2022, Nature Medicine
Participants: 304 adults, no diabetes
Duration: 104 weeks (2 years)

Results:

  • Semaglutide group: -15.2% body weight at 2 years
  • Placebo group: -2.6%

The two-year data shows that weight loss is maintained long-term as long as the medication is continued. Most of the loss occurs in the first 6-9 months, with a plateau and slight stabilization afterward. This pattern is consistent with what individual users report — the weight loss timeline on GLP-1 typically shows the most dramatic changes in the first several months.

SELECT: The Cardiovascular Outcomes Trial

Published: November 2023, New England Journal of Medicine
Participants: 17,604 adults aged 45+ with established cardiovascular disease and BMI ≥27, without diabetes
Duration: Up to 5 years (mean follow-up 39.8 months)

SELECT was the game-changer. This wasn't a weight loss trial — it was a cardiovascular outcomes trial, the gold standard for proving a drug saves lives.

Results:

  • 20% reduction in major adverse cardiovascular events (heart attack, stroke, cardiovascular death)
  • Mean weight loss of 9.4% in the semaglutide group vs 0.9% in placebo
  • Significant reductions in heart failure events and cardiovascular mortality

SELECT fundamentally repositioned semaglutide from a "weight loss drug" to a cardiovascular medication that also causes weight loss. It led to expanded insurance coverage and a shift in how the medical establishment views GLP-1 therapy. For a deeper look at how GLP-1 medications produce these effects, see our mechanism explainer.

How to Interpret "Average" Results

The most common mistake people make when reading these trials is treating the average as a guarantee. Here's what the distribution actually looks like:

  • ~10-15% of participants are "super responders" — they lose 25%+ of their body weight
  • ~50% lose 15% or more
  • ~85% lose at least 5%
  • ~10-15% are "non-responders" — they lose less than 5% or don't respond meaningfully

Factors that predict better response include: higher starting BMI (more to lose), absence of type 2 diabetes, younger age, female sex (slightly better average response), and adherence to lifestyle changes. But even within these categories, individual variation is substantial.

Placebo-Adjusted vs. Absolute Numbers

One common source of confusion is the difference between absolute weight loss and placebo-adjusted weight loss. When a trial reports "14.9% weight loss" in STEP 1, that's the absolute number. The placebo group lost 2.4%, so the placebo-adjusted effect of semaglutide is 12.4 percentage points.

Why does this matter? Because the placebo group was also following a calorie-restricted diet with exercise counseling. In the real world, where people aren't in a clinical trial with regular counseling sessions, the drug's effect might be even larger relative to no treatment at all — or smaller, if patients don't make any lifestyle changes.

For most people, the absolute number is more useful: if you take semaglutide 2.4mg and follow reasonable dietary guidance, you can expect to lose roughly 10-20% of your body weight over the first year, with individual results varying significantly based on biology, adherence, and starting point.

What the Data Can't Tell You

Clinical trials measure averages across populations. They can't tell you exactly how much you will lose, how your face will change, or how you will feel. For a personalized projection based on your specific stats and the clinical data ranges, try the MeOnGLP transformation tool — it applies these trial results to your body composition and shows you what the data predicts for someone like you.

The data is clear: semaglutide produces clinically significant, sustained weight loss in the majority of patients. The remaining questions — which drug is best, how to manage side effects, whether tirzepatide outperforms semaglutide — are what we'll explore in our other research breakdowns.